JP2008501038A5 - - Google Patents

Download PDF

Info

Publication number
JP2008501038A5
JP2008501038A5 JP2007515512A JP2007515512A JP2008501038A5 JP 2008501038 A5 JP2008501038 A5 JP 2008501038A5 JP 2007515512 A JP2007515512 A JP 2007515512A JP 2007515512 A JP2007515512 A JP 2007515512A JP 2008501038 A5 JP2008501038 A5 JP 2008501038A5
Authority
JP
Japan
Prior art keywords
cell lymphoma
cell
lymphoma
use according
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007515512A
Other languages
English (en)
Japanese (ja)
Other versions
JP5005532B2 (ja
JP2008501038A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/019169 external-priority patent/WO2005117891A1/en
Publication of JP2008501038A publication Critical patent/JP2008501038A/ja
Publication of JP2008501038A5 publication Critical patent/JP2008501038A5/ja
Application granted granted Critical
Publication of JP5005532B2 publication Critical patent/JP5005532B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007515512A 2004-05-30 2005-05-31 10−プロパルギル−10−デアザアミノプテリンを用いるt細胞リンパ腫の治療 Expired - Lifetime JP5005532B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52159304P 2004-05-30 2004-05-30
US60/521,593 2004-05-30
PCT/US2005/019169 WO2005117891A1 (en) 2004-05-30 2005-05-31 Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin

Publications (3)

Publication Number Publication Date
JP2008501038A JP2008501038A (ja) 2008-01-17
JP2008501038A5 true JP2008501038A5 (https=) 2008-06-26
JP5005532B2 JP5005532B2 (ja) 2012-08-22

Family

ID=34971703

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007515512A Expired - Lifetime JP5005532B2 (ja) 2004-05-30 2005-05-31 10−プロパルギル−10−デアザアミノプテリンを用いるt細胞リンパ腫の治療

Country Status (23)

Country Link
US (4) US7939530B2 (https=)
EP (1) EP1750716B1 (https=)
JP (1) JP5005532B2 (https=)
KR (1) KR101189693B1 (https=)
CN (2) CN102824346B (https=)
AT (1) ATE405272T1 (https=)
AU (1) AU2005249516B2 (https=)
BR (1) BRPI0510895A (https=)
CA (1) CA2565968C (https=)
DE (1) DE602005009176D1 (https=)
DK (1) DK1750716T3 (https=)
ES (1) ES2313365T3 (https=)
HR (1) HRP20080569T3 (https=)
ME (1) ME01087B (https=)
MX (1) MXPA06013559A (https=)
NO (1) NO337276B1 (https=)
NZ (2) NZ576849A (https=)
PL (1) PL1750716T3 (https=)
PT (1) PT1750716E (https=)
RS (1) RS50622B (https=)
SI (1) SI1750716T1 (https=)
WO (2) WO2005117891A1 (https=)
ZA (1) ZA200609266B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US8263354B2 (en) * 2004-05-30 2012-09-11 Sloan-Kettering Institute For Cancer Research Methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterin
US20080188479A1 (en) * 2004-05-30 2008-08-07 Sloan-Kettering Institute For Cancer Research Methods to Treat Cancer with 10-propargyl-10-deazaaminopterin and Methods for Assessing Cancer for Increased Sensitivity to 10-propargyl-10-deazaaminopterin
CA2565968C (en) 2004-05-30 2013-01-08 Sloan-Kettering Institute For Cancer Research Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
KR101335021B1 (ko) 2007-07-31 2013-12-12 액세라인크 게놈 테스트의 용도 및 인지 기능 저하 치료용 케톤성 화합물
US20100248249A1 (en) * 2007-08-17 2010-09-30 Allos Therapeutics, Inc. Methods for Assessing Cancer for Increased Sensitivity to 10-Propargyl-10-Deazaaminopterin by Assessing Egfr Levels
US9901578B2 (en) 2007-08-17 2018-02-27 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
WO2009026234A1 (en) * 2007-08-17 2009-02-26 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
US9125881B2 (en) 2008-07-03 2015-09-08 Accera, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
WO2010022277A2 (en) * 2008-08-20 2010-02-25 O'connor Owen A Combination of 10-propargyl-10-deazaaminopterin and bortezomib for the treatment of cancers
US20110190305A1 (en) 2010-02-02 2011-08-04 Allos Therapeutics, Inc. Optically Pure Diastereomers of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same
EP2575466B1 (en) * 2010-06-02 2015-04-08 Allos Therapeutics, Inc. Methods for treating methotrexate-resistant disorders with 10-propargyl-10-deazaaminopterin
US20130178441A1 (en) * 2010-08-10 2013-07-11 Allos Therapeutics, Inc. Methods for Extending Progression-Free Survival using 10-Propargyl-10-Deazaaminopterin
WO2013164856A1 (en) 2012-05-04 2013-11-07 Avra Laboratories Private Limited A process for preparing intermediates of 10-propargyl-10-deazaaminopterin (pralatrexate) synthesis and the intermediates thereof
CN103274943B (zh) * 2013-05-24 2015-01-21 苏州明锐医药科技有限公司 4-[1-(2-丙炔基)-3,4-二氧代正丁基]苯甲酸酯及其制备方法
WO2016205203A1 (en) 2015-06-16 2016-12-22 Spectrum Pharmaceuticals, Inc. Combination therapy using belinostat and pralatrexate to treat lymphoma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393064A (en) * 1976-03-05 1983-07-12 Sri International Process and composition for treatment of leukemia and process for preparing the same
US4652533A (en) * 1983-04-28 1987-03-24 Pandex Laboratories, Inc. Method of solid phase immunoassay incorporating a luminescent label
US4843155A (en) * 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
DE69133095T2 (de) * 1990-11-20 2003-03-27 Dade Behring Marburg Gmbh Cyclosporin-Immunoassay
US5354751A (en) * 1992-03-03 1994-10-11 Sri International Heteroaroyl 10-deazaamino-pterine compounds and use for rheumatoid arthritis
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US6323205B1 (en) * 1996-07-17 2001-11-27 Sloan-Kettering Institute For Cancer Research Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
PT944389E (pt) * 1996-07-17 2008-12-03 Sloan Kettering Inst Cancer Composições purificadas de 10-propargil-10-desaza-aminopterina e métodos para a sua utilização no tratamento de tumores
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
CA2565968C (en) * 2004-05-30 2013-01-08 Sloan-Kettering Institute For Cancer Research Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin

Similar Documents

Publication Publication Date Title
JP2008501038A5 (https=)
JP2008519047A5 (https=)
Rowinsky et al. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics
JP2024109585A5 (https=)
JP2006504795A5 (https=)
Schiller et al. Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer
JP2012506394A5 (https=)
JP2006512324A5 (https=)
JP2006516571A5 (https=)
JP2012107063A5 (https=)
JP2010529038A5 (https=)
ZA202213478B (en) Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
JP2005530735A5 (https=)
JP2020508351A5 (https=)
JP2013540734A5 (https=)
JP2022532038A5 (https=)
JP2009516719A5 (https=)
JP2002326936A5 (https=)
Spear et al. IN BRONCHOGENIC CARCINOMA, HODGKIN'S DISEASE, AND LYMPHOSARCOMA 3
RU2013102373A (ru) Продления выживаемости без прогрессирования заболевания с применением 10-пропаргил-10-деазааминоптерина
CN111163781B (zh) 用于治疗癌症的mdm2抑制剂与erk抑制剂的组合
CN111714500A (zh) 一种含柚皮素的药物组合物及其在治疗大肠癌上的应用
CN103417483A (zh) 盐酸美金刚缓释干混悬剂及其制备方法
JP2005513105A5 (https=)
Shanbrom et al. Therapeutic Spectrum of Uracil-Mustard, A New Oral Antitumor Drug: With Special Reference to the Effects of Small Dosage in Lymphomas, Chronic Leukemias, and Ovarian Carcinoma